ArticleCureus2024
Assessing Choroidal Neovascular Membrane Flow Regression Using Optical Coherence Tomography Angiography After a Single Injection of Faricimab in Age-Related Macular Degeneration: A Case Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case study aims to evaluate the regression of the vascular network in a patient with age-related macular degeneration (AMD) following a single injection of faricimab, utilizing optical coherence tomography angiography (OCTA) for detailed assessment. An elderly patient diagnosed with neovascular AMD received a single injection of faricimab, with pre and post-treatment OCTA imaging performed to assess changes in the choroidal neovascular membrane (CNVm) and surrounding retinal structures. OCTA revealed significant regression of the vascular network following the single injection of faricimab, demonstrating a marked reduction in blood flow within the CNV, which corresponded with structural and anatomical improvements in the retina. This case highlights the potential of faricimab to induce rapid regression of CNVm in AMD after a single injection, as observed through OCTA. Furthermore, while current monitoring primarily relies on OCT B-scan structural assessments, the flow dynamics captured by OCTA may play a crucial role in future treatment monitoring and therapeutic strategies for managing neovascular AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.